The Long-Term Serological Profile of CoronaVac Vaccine Based on Comorbidities and History of SARS-CoV-2 Infection in Indonesia.

IF 1.3 4区医学 Q4 INFECTIOUS DISEASES

Japanese journal of infectious diseases Pub Date : 2024-01-24 Epub Date: 2023-10-31 DOI:10.7883/yoken.JJID.2023.061

Syahrul Chilmi, Tanti Adelia Kesuma, Purwa Adrianta Wibawa, Hani Susianti, Agustin Iskandar, Indah Adhita Wulanda, Caesarius Singgih Wahono, Kusworini Handono

{"title":"The Long-Term Serological Profile of CoronaVac Vaccine Based on Comorbidities and History of SARS-CoV-2 Infection in Indonesia.","authors":"Syahrul Chilmi, Tanti Adelia Kesuma, Purwa Adrianta Wibawa, Hani Susianti, Agustin Iskandar, Indah Adhita Wulanda, Caesarius Singgih Wahono, Kusworini Handono","doi":"10.7883/yoken.JJID.2023.061","DOIUrl":null,"url":null,"abstract":"<p><p>CoronaVac is one of the most widely administered COVID-19 vaccines in Indonesia. Previous studies have documented its effectiveness in protecting against COVID-19 in several countries. This study aimed to assess the long-term immunogenicity of CoronaVac in individuals with comorbidities or a history of SARS-CoV-2 infection. The total anti-N Ig and anti-S-RBD Ig levels at 7 and 26 weeks after the second dose of vaccine were documented in 194 health workers. The participants were divided into groups based on their comorbidities and history of SARS-CoV-2 infection. The antibody titers did not differ according to comorbidity status or history of SARS-CoV-2 infection. The total anti-nucleocapsid Ig and total anti-S-RBD Ig levels were significantly lower in individuals without a history of SARS-CoV-2 infection. These results indicate that CoronaVac induces a lower specific antibody response than natural infection and less long-term immunogenicity.</p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese journal of infectious diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7883/yoken.JJID.2023.061","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

CoronaVac is one of the most widely administered COVID-19 vaccines in Indonesia. Previous studies have documented its effectiveness in protecting against COVID-19 in several countries. This study aimed to assess the long-term immunogenicity of CoronaVac in individuals with comorbidities or a history of SARS-CoV-2 infection. The total anti-N Ig and anti-S-RBD Ig levels at 7 and 26 weeks after the second dose of vaccine were documented in 194 health workers. The participants were divided into groups based on their comorbidities and history of SARS-CoV-2 infection. The antibody titers did not differ according to comorbidity status or history of SARS-CoV-2 infection. The total anti-nucleocapsid Ig and total anti-S-RBD Ig levels were significantly lower in individuals without a history of SARS-CoV-2 infection. These results indicate that CoronaVac induces a lower specific antibody response than natural infection and less long-term immunogenicity.

查看原文本刊更多论文

基于印尼合并症和严重急性呼吸系统综合征冠状病毒2型感染史的冠状病毒疫苗的长期血清学特征。

CoronaVac是印度尼西亚使用最广泛的新冠肺炎疫苗之一。先前的研究记录了几个国家关于其预防新冠肺炎有效性的各种数字。因此，本研究旨在评估有严重急性呼吸系统综合征冠状病毒2型合并症或感染史的个体的长期免疫原性。在194名卫生工作者中观察了在接受第二剂后7周和26周的总抗N Ig和抗S-RBD Ig水平。根据参与者的合并症和严重急性呼吸系统综合征冠状病毒2型感染史将其分为几组。结果显示，在没有任何严重急性呼吸系统综合征冠状病毒2型感染史的健康组和合并症组之间，两种抗体滴度没有差异。与感染组相比，总抗核衣壳Ig水平显著降低，并且在总抗S-RBD Ig水平上获得了类似的结果。根据研究结果，与自然感染相比，CoronaVac诱导的特异性抗体反应较低，长期来看也降低了免疫原性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese journal of infectious diseases 医学-传染病学

CiteScore

4.50

自引率

4.50%

发文量

172

审稿时长

2 months

期刊介绍： Japanese Journal of Infectious Diseases (JJID), an official bimonthly publication of National Institute of Infectious Diseases, Japan, publishes papers dealing with basic research on infectious diseases relevant to humans in the fields of bacteriology, virology, mycology, parasitology, medical entomology, vaccinology, and toxinology. Pathology, immunology, biochemistry, and blood safety related to microbial pathogens are among the fields covered. Sections include: original papers, short communications, epidemiological reports, methods, laboratory and epidemiology communications, letters to the editor, and reviews.